Breaking Finance News

Regeneron Reports Positive Phase 3 Results on EYLEA (REGN)

Tuesday morning, Regeneron Pharmaceuticals (NASDAQ: REGN) reported, along with Bayer HealthCare, that notable, positive outcomes were observed in Phase 3 studies of EYLEA for treatment of diabetic macular edema (DME).

According to the release, two groups, labeled VIVID-DME and VISTA-DME received either 2 mg of EYLEA monthly or every two weeks. The VIVID group went baseline in BCVA of 10.5 letters and the VISTA group from baseline in best-corrected visual acuity (BCVA) of 12.5 letters.

“We are pleased with these positive data in another potentially important indication for EYLEA,” said George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories.  “Diabetes is a growing disease worldwide and DME is a major cause of vision loss in people with diabetic retinopathy.  We hope to be able to offer a new treatment option for patients suffering from this potentially blinding retinal disease.”

EYLEA was approved in the United States for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) in November 2011 and for Macular Edema following Central Retinal Vein Occlusion (CRVO) in September 2012.  EYLEA has also been approved in Europe, Japan, Australia, and in several other countries for use in wet AMD.

[stock-tools exchange="NASDAQ" symbol="REGN" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

New to Breaking Finance News? Read about our format here.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.